Clinical standards for the management of adverse effects during treatment for TB
Author
Singh, K PCarvalho, A C C
Centis, R
D Ambrosio, L
Migliori, G B
Mpagama, S G
Nguyen, B C
Aarnoutse, R E
Aleksa, A
van Altena, R
Bhavani, P K
Bolhuis, M S
Borisov, S
van T Boveneind-Vrubleuskaya, N
Bruchfeld, J
Caminero, J A
Carvalho, I
Cho, J G
Davies Forsman, L
Dedicoat, M
Dheda, K
Dooley, K
Furin, J
García-García, J M
Garcia-Prats, A
Hesseling, A C
Heysell, S K
Hu, Y
Kim, H Y
Manga, S
Marais, B J
Margineanu, I
Märtson, A-G
Munoz Torrico, M
Nataprawira, H M
Nunes, E
Ong, C W M
Otto-Knapp, R
Palmero, D J
Peloquin, C A
Rendon, A
Rossato Silva, D
Ruslami, R
Saktiawati, A M I
Santoso, P
Schaaf, H S
Seaworth, B
Simonsson, U S H
Singla, R
Skrahina, A
Solovic, I
Srivastava, S
Stocker, S L
Sturkenboom, M G G
Svensson, E M
Tadolini, M
Thomas, T A
Tiberi, S
Trubiano, J
Udwadia, Z F
Verhage, A R
Vu, D H
Akkerman, O W
Alffenaar, J W C
Denholm, J T
Publication date
2023-07
Metadata
Show full item recordAbstract
BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.Citation
Singh KP, Carvalho ACC, Centis R, D Ambrosio L, Migliori GB, Mpagama SG, Nguyen BC, Aarnoutse RE, Aleksa A, van Altena R, Bhavani PK, Bolhuis MS, Borisov S, van T Boveneind-Vrubleuskaya N, Bruchfeld J, Caminero JA, Carvalho I, Cho JG, Davies Forsman L, Dedicoat M, Dheda K, Dooley K, Furin J, García-García JM, Garcia-Prats A, Hesseling AC, Heysell SK, Hu Y, Kim HY, Manga S, Marais BJ, Margineanu I, Märtson AG, Munoz Torrico M, Nataprawira HM, Nunes E, Ong CWM, Otto-Knapp R, Palmero DJ, Peloquin CA, Rendon A, Rossato Silva D, Ruslami R, Saktiawati AMI, Santoso P, Schaaf HS, Seaworth B, Simonsson USH, Singla R, Skrahina A, Solovic I, Srivastava S, Stocker SL, Sturkenboom MGG, Svensson EM, Tadolini M, Thomas TA, Tiberi S, Trubiano J, Udwadia ZF, Verhage AR, Vu DH, Akkerman OW, Alffenaar JWC, Denholm JT. Clinical standards for the management of adverse effects during treatment for TB. Int J Tuberc Lung Dis. 2023 Jul 1;27(7):506-519. doi: 10.5588/ijtld.23.0078. PMID: 37353868; PMCID: PMC10321364.Type
ArticlePMID
37353868ae974a485f413a2113503eed53cd6c53
10.5588/ijtld.23.0078